Vaskülitler ve Vitanin D
Özet
D vitamininin immün sistemi düzenleyici rolü ve otoimmün hastalıkların patogenezindeki yeri, vaskülitler bağlamında giderek daha fazla önem kazanmaktadır. Vaskülitler, damar duvarlarında inflamasyon ve nekrozla seyreden heterojen bir hastalık grubudur. Araştırmalar; Behçet hastalığı, Kawasaki hastalığı, Takayasu arteriti ve ANCA ilişkili vaskülit gibi farklı vaskülit türlerine sahip hastalarda serum D vitamini düzeylerinin sağlıklı kontrollere kıyasla anlamlı derecede düşük olduğunu göstermektedir. D vitamini eksikliği, bu hastalıklarda yüksek CRP ve ESR gibi inflamasyon parametreleri, artmış hastalık aktivitesi, koroner arter anomalileri ve böbrek tutulumu gibi ciddi klinik komplikasyonlarla yakından ilişkilendirilmiştir. Ayrıca aktif hastalık dönemlerinde D vitamini seviyelerinin daha da düştüğü, D vitamininin T hücre yanıtını proinflamatuar Th1 fenotipinden antiinflamatuar Th2 yönüne kaydırarak koruyucu bir etki yaratabileceği saptanmıştır. Uzun süreli kortikosteroid tedavisi alan vaskülit hastalarında kemik mineral yoğunluğunu korumak adına kalsiyum ve D vitamini takviyesi standart bir öneri olarak öne çıkmaktadır. Sonuç olarak, D vitamini düzeylerinin vaskülitlerde hastalık şiddeti ve takibi açısından klinik bir gösterge olabileceği, ancak tedavi edici etkilerinin tam olarak anlaşılması için daha kapsamlı çalışmalara ihtiyaç duyulduğu belirtilmektedir.
The regulatory role of vitamin D in the immune system and its involvement in the pathogenesis of autoimmune diseases are becoming increasingly important in the context of vasculitis. Vasculitis comprises a heterogeneous group of diseases characterized by inflammation and necrosis in vessel walls. Studies demonstrate that serum vitamin D levels in patients with various types of vasculitis—such as Behçet's disease, Kawasaki disease, Takayasu's arteritis, and ANCA-associated vasculitis—are significantly lower compared to healthy controls. Vitamin D deficiency in these diseases is closely associated with high inflammatory parameters like CRP and ESR, increased disease activity, and serious clinical complications including coronary artery abnormalities and renal involvement. Furthermore, vitamin D levels drop even further during active periods of the disease, and it has been observed that vitamin D may exert a protective effect by shifting the T-cell response away from the pro-inflammatory Th1 phenotype toward the anti-inflammatory Th2 direction. Calcium and vitamin D supplementation stands out as a standard recommendation to preserve bone mineral density in vasculitis patients receiving long-term corticosteroid therapy. In conclusion, while vitamin D levels could serve as a clinical marker for disease severity and monitoring in vasculitis, more comprehensive studies are required to fully clarify its therapeutic efficacy.
Referanslar
Munger K, Levin L, Hollis B, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. Jama 2006; 296(23):2832–38. doi: 10.1001/jama.296.23.2832.
Merlino L, Curtis J, Mikuls T, et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women’s Health Study. Arthritis Rheum 2004; 50(1):72–7. doi: 10.1002/art.11434.
Mouli V, Ananthakrishnan A. Review article: vitamin D and inflammatory bowel diseases. Aliment Pharmacol Ther 2014;39 (2):125–13. doi: 10.1111/apt.12553.
Shinkai K. Cutaneous vaculitis. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. 3rd ed. Vol 2. 2012:385-407. Saunders Elsevier, Philadelphia PA.
Demir S, Sönmez HE, Özen S. Vasculitis: Decade in Review. Curr Rheumatol Rev. 2019;15(1):14-22. doi: 10.2174/1573397114666180726093731.
Shavit E, Alavi A, Sibbald RG. Vasculitis-What Do We Have to Know? A Review of Literature. Int J Low Extrem Wounds. 2018;17(4):218-26. doi: 10.1177/1534734618804982.
Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37(2):187-92. doi: 10.1002/art.1780370206.
Jennette J, Falk R, Bacon P, et al. 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013; 65(1):1-11. doi: 10.1002/art.37715.
Watts RA, Robson J. Introduction, epidemiology and classification of vasculitis. Best Pract Res Clin Rheumatol. 2018;32(1):3-20. doi: 10.1016/j.berh.2018.10.003.
Micheletti RG, Pagnoux C. Management of cutaneous vasculitis. Presse Med. 2020;49(3):104033. doi: 10.1016/j.lpm.2020.104033.
Marzano AV, Vezzoli P, Berti E. Skin involvement in cutaneous and systemic vasculitis. Autoimmun Rev. 2013;12(4):467-76. doi: 10.1016/j.autrev.2012.08.005.
Guillevin L, Dörner T. Vasculitis: mechanisms involved and clinical manifestations. Arthritis Res Ther. 2007;9 Suppl 2(Suppl 2):9. doi:10.1186/ar2193
Salama AD. Genetics and pathogenesis of small-vessel vasculitis. Best Pract Res Clin Rheumatol. 2018;32(1):21-30. doi: 10.1016/j.berh.2018.10.002.
Sindrilaru A, Seeliger S, Ehrchen JM, et al. Site of blood vessel damage and relevance of CD18 in a murine model of immune complex-mediated vasculitis. J Invest Dermatol. 2007;127(2):447-54. doi: 10.1038/sj.jid.5700563.
Kermani TA. Takayasu arteritis and giant cell arteritis: are they a spectrum of the same disease? Int J Rheum Dis. 2019;22 Suppl 1:41-8. doi: 10.1111/1756-185X.13288
Sassi F, Tamone C, D’Amelio P. Vitamin D: Nutrient, Hormone, and Immunomodulator. Nutrients.2018;10(11):1656. doi: 10.3390/nu10111656.
Leventis P, Patel S. Clinical aspects of vitamin D in the management of rheumatoid arthritis. Rheumatology (Oxford). 2008;47(11):1617-21. doi: 10.1093/rheumatology/ken296.
Henry HL. Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab. 2011;25(4):531–41. doi: 10.1016/j.beem.2011.05.003.
Carlberg C, Seuter S, Heikkinen S. The first genome-wide view of vitamin D receptor locations and their mechanistic implications. Anticancer Res. 2012;32 (1):271–82.
Saccone D, Asani F, Bornman L. Regulation of the vitamin D receptor gene by environment, genetics and epigenetics. Gene. 2015;561(2):171‐80. doi: 10.1016/j.gene.2015.02.024.
Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25- Dihydroxyvitamin D3 receptors in human leukocytes. Science 1983;221(4616):1181–3. doi: 10.1126/science.6310748.
Shoenfeld N, Amital H, Shoenfeld Y. The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease. Nat Clin Pract Rheumatol 2009;5(2):99–105. doi: 10.1038/ncprheum0989.
Cantorna MT, Yu S, Bruce D. The paradoxical effects of vitamin D on type 1 mediated immunity. Mol Aspects Med 2008;29(6):369–75. doi: 10.1016/j.mam.2008.04.004.
Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 2007;66(9):1137–42. doi: 10.1136/ard.2007.069831.
Jirapongsananuruk O, Melamed I, Leung DY. Additive immunosuppressive effects of 1, 25-dihydroxyvitamin D3 and corticosteroids on TH1, but not TH2, responses. J Allergy Clin Immunol 2000;106(5):981–5. doi: 10.1067/mai.2000.110101.
Lemire J. 1, 25-dihydroxyvitamin D3 — a hormone with immunomodulatory properties. Z Rheumatol. 2000;59(Suppl 1):24–7. doi: 10.1007/s003930070034.
Chen S, Sims GP, Chen XX, et al. Modulatory effects of 1, 25- dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007;179(3):1634–47. doi: 10.4049/jimmunol.179.3.1634.
Borel P, Caillaud D, Cano NJ. Vitamin D bioavailability: state of the art. Crit Rev Food Sci Nutr.2015;55(9):1193–205. doi: 10.1080/10408398.2012.688897.
Illescas-Montes R, Melguizo-Rodriguez L, Ruiz C, Costela-Ruiz VJ. Vitamin D and autoimmune diseases. Life Sci. 2019;233:116744. doi: 10.1016/j.lfs.2019.116744.
Bikle DD. Vitamin D and the skin: Physiology and pathophysiology. Rev Endocr Metab Disord. 2012;13(1):3-19. doi:10.1007/s11154-011-9194-0
Dall’Ara F, Cutolo M, Andreoli L, et al. Vitamin D and systemic lupus erythematous: a review of immunological and clinical aspects. Clin Exp Rheumatol. 2018;36(1):153–62.
Mateen S, Moin S, Shahzad S, Khan AQ. Level of inflammatory cytokines in rheumatoid arthritis patients: Correlation with 25-hydroxy vitamin D and reactive oxygen species. PLoS ONE 2017;12(6):e178879. doi: 10.1371/journal.pone.0178879.
Guan SY, Cai HY, Wang P, et al. Association between circulating 25-hydroxyvitamin D and systemic lupus erythematosus: a systematic review and meta-analysis. Int J Rheum Dis. 2019;22(10):1803–13. doi: 10.1111/1756-185X.13676.
Hausmann J, Kubesch A, Amiri M, et al. Vitamin D deficiency is associated with increased disease activity in patients with inflammatory bowel disease. J Clin Med. 2019; 8(9):1319. doi: 10.3390/jcm8091319.
Sadeghi K, Wessner B, Laggner U, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol. 2006;36(2):361-70. doi: 10.1002/eji.200425995.
Hamzaoui K, Ben Dhifallah I, Karray E, et al. Vitamin D modulates peripheral immunity in patients with Behçet's disease. Clin Exp Rheumatol. 2010;28(4 Suppl 60):50-7.
Correale J, Ysrraelit MC, Gaitán MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain. 2009 May;132(Pt 5):1146-60. doi: 10.1093/brain/awp033.
Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol. 2008;194(1-2):7-17. doi: 10.1016/j.jneuroim.2007.11.014.
Stagi S, Rigante D, Lepri G, et al. Severe vitamin D deficiency in patients with Kawasaki disease: a potential role in the risk to develop heart vascular abnormalities? Clin Rheumatol. 2016;35(7):1865-72. doi: 10.1007/s10067-015-2970-6.
Jun JS, Jung YK, Lee DW. Relationship between vitamin D levels and intravenous immunoglobulin resistance in Kawasaki disease. Korean J Pediatr. 2017;60(7):216-20. doi:10.3345/kjp.2017.60.7.216.
SuzukiY, IchiyamaT, OhsakiA, et al. Anti‑inflammatory effect of 1‑alpha, 25‑dihydroxyvitamin D(3) in human coronary arterial endothelial cells: Implication for the treatment of Kawasaki disease. J Steroid Biochem Mol Biol. 2009;113(1-2):134‑8. doi: 10.1016/j.jsbmb.2008.12.004.
Kudo K, Hasegawa S, Suzuki Y, et al. 1α, 25‑Dihydroxyvitamin D(3) inhibits vascular cellular adhesion molecule‑1 expression and interleukin‑8 production in human coronary arterial endothelial cells. J Steroid Biochem Mol Biol. 2012;132(3-5):290‑4. doi: 10.1016/j.jsbmb.2012.07.003.
Riek AE, Oh J, Bernal‑Mizrachi C. 1,25(OH)2 vitamin D suppresses macrophage migration and reverses atherogenic cholesterol metabolism in type 2 diabetic patients. J Steroid Biochem Mol Biol. 2013;136:309‑12. doi: 10.1016/j.jsbmb.2012.12.019.
Arnson Y, Itzhaky D, Mosseri M, et al. Vitamin D inflammatory cytokines and coronary events: A comprehensive review. Clin Rev Allergy Immunol 2013;45(2):236‑47. doi: 10.1007/s12016‑013‑8356‑0.
Liao H, Pan LL, Du J, Wang T. Relationships between the levels of serum 25-hydroxyvitamin D and interleukin-6 in patients with Takayasu's arteritis. Zhonghua Yi Xue Za Zhi. 2018;98(43):3509-12. Chinese. doi: 10.3760/cma.j.issn.0376-2491.2018.43.009. (Abstract).
Alibaz-Oner F, Asmaz-Haliloglu Ö, Gogas-Yavuz D, et al. Vitamin D Levels in Takayasu's Arteritis and a Review of the Literature on Vasculitides. J Clin Lab Anal. 2016;30(5):529-33. doi: 10.1002/jcla.21898.
Gatenby PA, Lucas RM, Engelsen O, et al. Antineutrophil cytoplasmicantibody-associated vasculitides: could geographic patterns be explained by ambient ultraviolet radiation? Arthritis Rheum. 2009;61(10):1417–24. doi: 10.1002/art.24790.
Yoon T, Ahn SS, Pyo JY, et al. Serum vitamin D level correlates with disease activity and health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis. Z Rheumatol. 2020 Dec 18. English. doi: 10.1007/s00393-020-00949-2.
Kemna MJ, Cohen Tervaert JW, Broen K, et al. Seasonal Influence on the Risk of Relapse at a Rise of Antineutrophil Cytoplasmic Antibodies in Vasculitis Patients with Renal Involvement. J Rheumatol. 2017;44(4):473-81. doi: 10.3899/jrheum.160066.
Perez MO, Oliveira RM, Levy-Neto M, et al. Serum 25-hydroxyvitamin D levels in patients with Granulomatosis with Polyangiitis: association with respiratory infection. Clinics (Sao Paulo). 2017;72(12):723-8. doi: 10.6061/clinics/2017(12)02.
Korkmaz FN, Ozen G, Unal AU, et al. Vitamin D Levels in Patients With Small and Medium Vessel Vasculitis. Reumatol Clin (Engl Ed). 2021; 13:S1699-258X(20)30275-8. English, Spanish. doi: 10.1016/j.reuma.2020.11.004.
Buckley L, Guyatt G, Fink HA, et al. American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–37. doi: 10.1002/art.40137.
Lapraik C, Watts R, Bacon P, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford). 2007;46(10):1615–6. doi: 10.1093/rheumatology/kem146a.
Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000;1998(2):CD000952. doi: 10.1002/14651858.CD000952.
Meyer K, Volkmann A, Hufnagel M, et al. Breastfeeding and vitamin D supplementation reduce the risk of Kawasaki disease in a German population-based case-control study. BMC Pediatr. 2019; 26;19(1):66. doi: 10.1186/s12887-019-1438-2.
